Fortress Biotech Forms New Subsidiary, Caelum Biosciences,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
111
Fortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis

Caelum Program Evaluating CAEL-101 (11-1F4) for AL Amyloidosis In-licensed from Columbia University

Data from ongoing Phase 1a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 is safe and well tolerated; 67 percent of patients showed improvement in organ function

Michael Spector to Serve as Chief Executive Officer

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO ) today announced the formation of a new subsidiary company, Caelum Biosciences, Inc., to advance the development of CAEL-101 (11-1F4) for the treatment of amyloid light chain (“AL”) amyloidosis. Caelum has entered into an agreement with Columbia University (“Columbia”) to secure exclusive worldwide license rights to CAEL-101, a chimeric fibril-reactive monoclonal antibody (mAb) currently being evaluated in a Phase 1a/1b study. In addition, Fortress announced the appointment of Michael Spector as Caelum’s Chief Executive Officer.

AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded amyloid proteins produced by plasma cells cause buildup in and around tissues, nerves and organs, gradually affecting their function. This can cause progressive and widespread organ damage, and high mortality rates.

Alan Solomon, M.D., Professor of Medicine Emeritus and a former American Cancer Society Clinical Research Professor at the University of Tennessee Graduate School of Medicine, who pioneered early development of antibodies that work to break up pre-existing amyloid in tissues and oversaw preclinical research on CAEL-101, said: “Existing AL amyloidosis treatment using chemotherapy eliminates the plasma cells that produce the abnormal proteins, but most often the pathologic amyloid deposits in the body’s vital tissues remain or progress, resulting in organ failure and even death. For this reason, our research efforts were focused on helping the body’s immune system remove this deleterious material. Our “anti-amyloid” monoclonal antibody 11-1F4, now designated CAEL-101, has demonstrated its ability to bind to amyloid and promote dissolution in mice bearing human AL amyloid tumors. Most importantly, CAEL-101 injection has been shown to specifically bind to the amyloid and not to normal tissue in patients with AL amyloidosis. We hope that this anti-amyloid immunotherapy, in combination with anti-plasma cell chemotherapy, will benefit patients with this fatal disease.”

Dr. Lindsay A. Rosenwald, Fortress Biotech’s Chairman, President and Chief Executive Officer, said, “We are thrilled to enter this collaboration with Columbia to advance the development of CAEL-101. The launch of Caelum, Fortress Biotech’s eighth subsidiary, underscores our mission of developing a broad pipeline of novel products across areas of unmet need.”

CAEL-101 Phase 1a/1b Study Update Data from an ongoing Phase 1a/1b study ( ClinicalTrials.gov Identifier: NCT02245867 ) have demonstrated that CAEL-101 is well tolerated and safe with no drug-related grade four or five adverse events or dose-limiting toxicity up to 500mg/m 2 . A single infusion of CAEL-101 or one weekly infusion for four weeks have demonstrated early and sustained organ response in cardiac, renal, gastrointestinal, skin and soft tissue. Interim clinical efficacy data show CAEL-101 promotes amyloid resolution in 67 percent of patients (63 percent in Phase 1a; 70 percent in Phase 1b). These data were presented by Columbia University on December 5, 2016 at the American Society of Hematology’s (ASH) 58th Annual Meeting.

Suzanne Lentzsch, M.D., Ph.D., Professor of Medicine at Columbia University Medical Center, College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital, and the principle investigator on the Phase 1a/1b study, said, “These interim results demonstrate strong biomarker activity that may speak to CAEL-101’s ability to safely promote amyloid elimination and the subsequent improvement of organ function. We look forward to working with Caelum on this promising program and expect to report full Phase 1a/1b data in the first half of 2017 and initiate a Phase 2 study in 2018.”

Michael Spector Named Chief Executive Officer Michael Spector joins Caelum from Fortress, Caelum’s parent company.  At Fortress, Michael has leveraged his more than 25 years of experience in biotechnology to identify emerging and innovative technologies to launch as new biotech and specialty pharmaceutical companies. Before joining Fortress, Mr. Spector served as Senior Vice President, Global Commercial Operations at Iroko Pharmaceuticals. Earlier in his career, he spent 15 years at GlaxoSmithKline in multiple senior management positions, including Vice President and General Manager of GlaxoSmithKline South Africa, where he led the overall business strategy and was elected to run the South African Pharmaceutical Manufacturers Association. Mr. Spector is also a founding member of Windhoek Healthcare, where he launched two specialty pharmaceutical companies: Laurel Pharmaceuticals and North Creek Pharmaceuticals.

Mr. Spector holds an M.B.A. from Rider University in Lawrenceville, N.J., where he serves on the school’s Business and Scientific Advisory Boards, and a B.S. in biology from the University of Pittsburgh. He also serves on the board of Jacaranda Health, a nonprofit organization that seeks to transform maternal and neonatal healthcare in East Africa.

About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies.  Additionally, Fortress recently acquired a controlling interest in National Holdings Corporation (NASDAQ: NHLD ), a diversified independent brokerage company (together with its subsidiaries, “NHLD”). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com .

Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.

Contacts: Caelum Biosciences, Inc. Michael Spector 212-574-2811 mspector@fortressbiotech.com Fortress Biotech, Inc. Lucy Lu, MD, Executive Vice President & Chief Financial Officer (781) 652-4500 ir@fortressbiotech.com Fortress Biotech Media Relations Laura Bagby 6 Degrees (312) 448-8098 lbagby@6degreespr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 6

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 109

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 84

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 129

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 92

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 78

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 135

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 20

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 74

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 128

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Greenlight Capital Re's Q4 and Annual Results

Updated Category News Views 139

Greenlight Capital Re, Ltd. Plans Future Financial Release Greenlight Capital Re, Ltd. (NASDAQ: GLRE), a leading multiline property and casualty insurer and reinsurer, has announced its schedule for releasing financial results for the fourth quarter and full year, which ended on December 31, 2024. The company is set to disclose these important results after the market...

Continue Reading
Integral Ad Science Holdings Faces Shareholder Lawsuit Insights

Updated Category News Views 125

Integral Ad Science's Shareholder Alert Integral Ad Science Holding Corp. (NASDAQ: IAS) is currently grappling with a significant legal challenge. A class action lawsuit has been filed against the company, alerting shareholders of their rights and options. Investors linked to the company should be aware of these developments as they navigate their positions in the market....

Continue Reading
Corcoran Expands Internationally with New Franchise Launch

Updated Category News Views 145

Corcoran Launches New Franchise in Mexico Corcoran Group LLC has taken a significant step in its expansion strategy by announcing the launch of its first franchise in Mexico, named Corcoran The Baja Real Estate Co. Led by Blake Harrington, this new brokerage is set to serve clients in the vibrant area surrounding Cabo San Lucas. This strategic move underscores Corcoran's...

Continue Reading
Titan Mining Announces Details for Upcoming AGM Meeting

Updated Category News Views 263

Titan Mining Corporation's Upcoming Annual General Meeting Titan Mining Corporation (TSX: TI; OTCQB: TIMCF) is set to hold its annual general meeting soon, a much-anticipated event for shareholders and stakeholders alike. The date is indeed significant as it marks an opportunity for the company to engage directly with its investors. Meeting Details and Importance The...

Continue Reading
Investing in EQT: A 20-Year Journey of Growth and Returns

Updated Category News Views 182

Understanding EQT Corporation's Investment Landscape EQT Corporation (NYSE: EQT) has shown substantial growth in the investment landscape over the past two decades. Over this period, EQT has consistently outperformed the market by 10.28% on an annualized basis, resulting in an impressive average annual return of 18.48%. This growth has contributed to EQT's current market...

Continue Reading